Type and Mechanisms of Residual Asthma Exacerbations in Patients Treated With Mepolizumab

What this Trial Is About

Researchers are studying the types and causes of asthma flare-ups that still occur in patients treated with mepolizumab, a medication for severe asthma. This observational study will follow patients over two years to understand the nature of remaining asthma exacerbations and how they relate to inflammation. The study is sponsored by Laval University and focuses on severe asthma patients eligible for mepolizumab treatment. Participants will receive 100 mg of mepolizumab as a subcutaneous injection every four weeks. They will be assessed before starting treatment and then every six months for two years. Additional assessments will take place whenever they experience moderate or severe asthma exacerbations during the study. Researchers will analyze sputum samples to determine the type of inflammation involved in these flare-ups. During study visits, patients will have clinical, physiological, and inflammatory evaluations, including lung function tests and inflammation markers. Outcome measures include the proportion of eosinophilic versus non-eosinophilic exacerbations, changes in asthma control questionnaire scores, lung function measures, and levels of inflammatory cells in sputum over 24 months. The study will closely monitor participants throughout the two-year period to better characterize residual asthma flare-ups under mepolizumab treatment.

Residual Exacerbations With Mepolizumab